[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577434":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":10,"centralContacts":46,"locations":10,"responsibleParty":52,"collaborators":56,"id":63,"slug":10,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":10,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":10},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"D subtype",null,"Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Depleted (D, TSR-low\\&sTIL-low)",[13],"Drug: Chemotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"F subtype","Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Fibrotic (F, TSR-high\\&sTIL-low)",[18],"Drug: Chemotherapy combined with immunotherapy",{"label":20,"type":10,"description":21,"interventionNames":22},"IE subtpye","Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Immune Enriched, Non-Fibrotic (IE, TSR-low\\&sTIL-high)",[23],"Drug: Immunotherapy",{"label":25,"type":10,"description":26,"interventionNames":27},"IE\u002FF subtype","Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Immune Enriched and Fibrotic (IE\u002FF, TSR-high\\&sTIL-high)",[28],"Drug: ADC",[30,35,39,43],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"DRUG","Chemotherapy","Gemicitabin and cisplatin",[9],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Immunotherapy","PD-1\u002FPD-L1",[20],{"type":31,"name":40,"description":41,"armGroupLabels":42,"otherNames":10},"ADC","ADC drug like RC48",[25],{"type":31,"name":44,"description":44,"armGroupLabels":45,"otherNames":10},"Chemotherapy combined with immunotherapy",[15],[47],{"name":48,"role":49,"phone":50,"phoneExt":10,"email":51},"Chunru Doc. Xu, M.D.","CONTACT","+86-17812172086","xcrbdyy@126.com",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Xuesong Li","Director of Department of Urology, Peking University First Hospital",[57,59,61],{"name":58,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"name":60,"class":6},"Peking University Third Hospital",{"name":62,"class":6},"Fujian Provincial Hospital","100577434",false,"NCT06798246","HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study","Hematoxylin-eosin Staining-based Tumor Microenvironment Subtype System Adjuvant Therapeutic Selection for Locally Advanced Upper Tract Urothelial Carcinoma After Radical Surgery：A Perspective Cohort Study","Inclusion Criteria:\n\n* pathological diagnose of UTUC;\n* Met more than muscle-invasion stages(pT2+) or lymph nodes metastasis.\n\nExclusion Criteria:\n\n* Patients with early-local stages (pTa\u002FT1\u002FTis) without LNM+ and those with incomplete pathologic and prognostic information were excluded","ALL","18 Years","80 Years",{"count":73,"type":74},200,"ESTIMATED","OBSERVATIONAL","This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.",[78],"Upper Tract Urothelial Carcinoma",[80,81,82,83],"HE-stained slides","Tumor microenvironment","Precise subtype","Adjuvant therapy","NOT_YET_RECRUITING","2025-01-22",{"date":87,"type":88},"2025-01-29","ACTUAL",{"date":90,"type":74},"2025-02-01",{"date":92,"type":74},"2030-01-01",{"name":5,"class":6}]